Alessandra Raimondi

@istitutotumori.mi.it

Medical Oncologist at Medical Oncology Department
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Alessandra Raimondi


            Download Compact PDF  
https://researchid.co/alessandra.raimondi

RESEARCH, TEACHING, or OTHER INTERESTS

Cancer Research
84

Scopus Publications

Scopus Publications

  • Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
    D. Ciardiello, G. Martini, L. Boscolo Bielo, F. Pietrantonio, A. Raimondi, P. Manca, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A. Cogoni, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, T. Troiani, F. De Vita, E. Martinelli, F. Ciardiello, S. Napolitano, Davide Ciardiello, Giulia Martini, Luca Boscolo Bielo, Filippo Pietrantonio, Alessandra Raimondi, Paolo Manca, Salvatore Pisconti, Claudia Nisi, Giampaolo Tortora, Lisa Salvatore, Andrea Sartore-Bianchi, Salvatore Siena, Livio Blasi, Elena Ongaro, Alberto Zaniboni, Carmine Pinto, Lorenzo Antonuzzo, Antonio Avallone, Nicola Normanno, Giuseppe Santabarbara, Maria Giulia Zampino, Rossana Berardi, Alessio Cogoni, Claudio Lotesoriere, Tiziana Pia Latiano, Evaristo Maiello, Nicola Fazio, Giuseppe Curigliano, Roberto Bordonaro, Teresa Troiani, Ferdinando De Vita, Erika Martinelli, Fortunato Ciardiello, Stefania Napolitano, Marco Messina, Elisa Sperti, Fabio Fulfaro, Silvana Leo, Davide Melisi, Alessandro Pastorino, Emiliano Tamburini, Antonietta Fabbrocini, Laura Matteucci
    Annals of Oncology, 2026
  • Early- and advanced-stage MSI-H non-colorectal cancers: best management and challenges in 2025
    R. Fazio, M. Ambrosini, A. Raimondi, C.C. Pircher, C. Leli, C. Sciortino, S. Marchesi, C. Damonte, C. Villa, C. Silvestri, F. Manoni, G. Gronchi, F. Pietrantonio
    ESMO Gastrointestinal Oncology, 2026
    Gastrointestinal malignancies account for the vast majority of tumours within the microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) phenotype. Over the past decade, evidence on the prognostic and predictive role of MSI-H/dMMR status has steadily accumulated, and immune checkpoint inhibitors (ICIs) are now considered the cornerstone of treatment for all patients with advanced MSI-H/dMMR cancers. However, in non-colorectal tumours the available evidence is less robust, raising important challenges, such as defining the optimal therapeutic regimen across different treatment lines and establishing the appropriate duration of therapy. More recently, the efficacy of ICIs has also been demonstrated in localized disease, prompting new questions regarding their integration into curative-intent strategies, such as the risk of overtreatment given the favourable prognosis of early-stage tumours, the role of nonoperative management, the optimal treatment regimen, and schedule. In this review, we summarize the available literature and the evidence supporting treatment strategies for patients with early- and advanced-stage MSI-H/dMMR non-colorectal cancers.
  • Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
    Vincenzo Nasca, Francesca Bergamo, Luisa Foltran, Lorenzo Antonuzzo, Katia Bencardino, Emanuela Dell’Aquila, Salvatore Corallo, Andrea Spallanzani, Oronzo Brunetti, Daniele Spada, Stefano Tamberi, Chiara Alessandra Cella, Antonio Avallone, Lorenzo Fornaro, Samantha Di Donato, Antonia Strippoli, Alberto Puccini, Emiliano Tamburini, Federica Palermo, Federica Morano, Filippo Pietrantonio, Alessandra Raimondi
    BMC Cancer, 2025
    BACKGROUND: The standard treatment for localized/locally advanced gastroesophageal adenocarcinoma (GEA) is radical surgery and peri-operative FLOT treatment (5-fluorouracil plus leucovorin, oxaliplatin, and docetaxel), but around half patients still experience disease relapse. In gastrointestinal cancers, the presence of circulating tumor DNA (ctDNA) after surgery is associated with a high risk of relapse, and the lack of ctDNA clearance after post-operative treatment is strongly associated with early relapse. Therefore, liquid biopsy may guide the selection of patients with micrometastatic disease after preoperative chemotherapy and surgery for non-cross resistant regimens in the post-operative setting. Trastuzumab deruxtecan (T-DXd) is approved in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma after failure of at least one prior trastuzumab-based regimen. The DESTINY-Gastric01 and 02 trials showed remarkable activity and efficacy of T-DXd, thus supporting the investigation of this agent in early-stage disease to increase the chance of achieving disease eradication. Finally, the DESTINY-Gastric03 trial showed the safety profile and feasibility, with preliminary promising activity results of the combination of T-DXd with a fluoropyrimidine. TRIAL DESIGN: TRINITY is an ongoing multicentre, randomized, open-label, interventional phase II study which will enroll approximately 46 patients with HER2-positive GEA, treated with pre-operative FLOT and radical surgery, and with the persistence of minimal residual disease detected by the Signatera™ assay in a liquid biopsy collected between 2 and 6 weeks after surgery. The trial is designed with an observational phase enrolling patients with HER2-positive GEA eligible for standard treatment with peri-operative FLOT and surgery. Eligible patients will be randomized on a 1:1 basis to the experimental treatment arm consisting of adjuvant T-DXd (6.4 mg/kg IV on day 1) plus either capecitabine (1000 mg/sqm BID orally on days 1-14) or 5-fluorouracil (600 mg/sqm continuous IV infusion on days 1-5) Q3 W for 6 cycles, or to the control arm with standard post-operative FLOT (at the same dose used during the last pre-operative cycle) for 4 cycles. Patients non-eligible for the interventional trial will continue the standard therapy and follow-up in the frame of the observational phase with collection of exploratory longitudinal liquid biopsies. The primary objective is ctDNA clearance at 1 year after randomization. Considering alpha- and beta-errors of 0.10 and 0.20 and hypothesizing a ctDNA clearance of 10% and 35% in the control and experimental arm, respectively, 23 patients per arm are required to prove the superiority of the experimental strategy. Secondary endpoints include disease-free survival, overall survival, metastases-free survival, patient-reported outcomes and safety. The trial also represents a translational platform, including extensive analysis of circulating, tissue, and immune biomarkers as exploratory endpoints. Enrollment is active and ongoing. TRIAL REGISTRATION: TRINITY is registered at ClinicalTrials.gov (NCT06253650).
  • Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials
    Alexej Ballhausen, Federica Morano, Arndt Stahler, Sara Lonardi, Andreas Jay Kind, Chiara Cremolini, Susanna Swoboda, Giovanni Randon, David Horst, Michele Prisciandaro, Annabel Helga Sophie Alig, Chiara Carlotta Pircher, Armin Jarosch, Paola Andena, Annika Kurreck, Anna Alessandra Chiaramonte, Sebastian Stintzing, Filippo Pietrantonio, Dominik Paul Modest, Alessandra Raimondi
    British Journal of Cancer, 2025
    BACKGROUND: Patients with RAS wild-type (WT), left-sided metastatic colorectal cancer (mCRC), negatively hyperselected for anti-EGFR resistance alterations, benefit most from anti-EGFR-based first-line treatment. The predictive impact of these stratification parameters on maintenance strategy efficacy is unclear. METHODS: This pooled analysis included individual patient data from the PanaMa (NCT01991873) and Valentino (NCT02476045) phase 2 trials. Patients with RAS WT mCRC received FOLFOX plus Panitumumab induction therapy followed by maintenance with 5-fluorouracil/leucovorin (5-FU/LV) plus Panitumumab vs. 5-FU/LV monotherapy (PanaMa) or Panitumumab monotherapy (Valentino). Outcomes included progression-free survival (PFS) and overall survival (OS). Subgroup analyses examined primary tumor sidedness (left vs. right) and hyperselection status (negative vs. altered). RESULTS: Among 607 patients receiving induction, sidedness and hyperselection status were available for 589 and 511 patients, respectively. Left-sided and negative hyperselected tumors were observed in 80.2% and 63.9% of patients, respectively. Panitumumab-based maintenance improved PFS in left-sided, negative hyperselected patients compared to 5-FU/LV alone, with no OS differences. PFS and OS were comparable for Panitumumab alone vs. Panitumumab plus 5-FU/LV. CONCLUSION: Tumor sidedness and hyperselection status significantly influence maintenance strategy efficacy in mCRC. For left-sided, negative hyperselected patients, Panitumumab monotherapy may optimize efficacy while minimizing toxicity. Further investigation into the relative contribution of individual hyperselection parameters in this setting is warranted.
  • Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis
    Alessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, Sara Lonardi, David Tougeron, Gianmarco Ricagno, Floriana Nappo, Ferdinando De Vita, Matthew Nankivell, David Cunningham, Jeeyun Lee, Won Ki Kang, Jae-Ho Cheong, Yoon Young Choi, Giovanni Randon, Michele Prisciandaro, Chiara C. Pircher, Paolo Manca, Margherita Ambrosini, Roberta Fazio, Francesca Bergamo, Guillaume Piessen, Elizabeth C. Smyth, Dominik Paul Modest, Rosalba Miceli, Thierry André, Filippo Pietrantonio
    Journal of Clinical Oncology, 2025
    PURPOSE Patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) resectable gastroesophageal adenocarcinoma (GEA) have better survival after surgery and scant/no benefit from chemotherapy. Preoperative immune checkpoint inhibitors (ICIs) demonstrated a high proportion of major complete pathologic response, possibly allowing chemotherapy/surgery-free approaches. METHODS Individual patient data pooled analysis was performed to determine an optimal strategy for resectable dMMR/MSI-H GEA. Patients were stratified across four groups: neoadjuvant dual CTLA-4/PD-(L)1 ICIs with or without surgery, perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) and surgery, and surgery alone or with older perioperative/adjuvant chemotherapy regimens. Primary end points were pathologic complete and major complete pathologic response proportion (pathologic complete response [pCR], tumor regression grade [TRG]1a, major pathologic response [MPR], TRG1a/b Becker criteria) in resected patients. Secondary end points were event-free survival (EFS) and overall survival (OS) in the overall population. RESULTS Among 197 patients, 49 received ICIs, 27 FLOT, 33 surgery alone, and 88 older chemotherapy regimens. Among 69 patients who underwent surgery after ICIs or FLOT, ICIs demonstrated significantly higher pathologic response versus FLOT (pCR, 61.9% v 3.7%; odds ratio [OR], 54.8; P = .002; MPR, 78.6% v 10%; OR, 39.3; P < .001) and lower ypN+ (14.3% v 37%; OR, 4.2; P = .015) and ypT (OR, 16.4; P < .001) stage. No significant differences in EFS/OS were observed (the 36-month EFS and OS were 70.4% v 80.6% and 72.7% v 90.4% with ICI v surgery alone). Residual nodal disease (ypN+) or ypT4 status after neoadjuvant ICIs or FLOT and nonpathologic response status were associated with inferior progression-free survival/OS. CONCLUSION In resectable dMMR/MSI-H GEA, neoadjuvant ICIs significantly increase pathologic response and downstaging versus FLOT, with comparable EFS/OS with surgery with or without chemotherapy. The higher proportion of ypN0 and lack of ypT4 after neoadjuvant ICIs versus FLOT should drive preoperative treatment choices in clinical high-risk disease. The high proportion of pCR/MPR with ICIs provides rationale for exploring organ-sparing surgery or nonoperative management.
  • Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial
    R. Fazio, G. Randon, F. Bergamo, F. Palermo, S. Tamberi, E. Giommoni, S. Di Donato, L. Fornaro, O. Brunetti, F. De Vita, M. Valgiusti, S.M. Gobba, A. Spallanzani, S. Murgioni, V. Bethaz, A. Strippoli, T.P. Latiano, G.G. Cardellino, C. Ceccon, A. Raimondi, M. Prisciandaro, C.C. Pircher, M. Ambrosini, P. Manca, M. Fassan, M. Di Bartolomeo, M. Di Maio, F. Pietrantonio
    ESMO Open, 2025
    BACKGROUND: There is a growing interest in optimizing the therapeutic management of older cancer patients as well as understanding the sex-specific differences in terms of efficacy and safety of cancer treatments. However, limited data are available on the initial therapy of patients with advanced gastro-oesophageal cancer. MATERIALS AND METHODS: The ARMANI phase III trial showed progression-free survival (PFS) and overall survival (OS) benefit with paclitaxel plus ramucirumab switch maintenance (arm A) versus the continuation of first-line oxaliplatin and fluoropyrimidine (arm B) in patients with advanced human epidermal growth factor receptor 2-negative gastric or gastro-oesophageal junction cancer. We conducted a subgroup analysis aimed at assessing the differences in efficacy, safety and quality of life (QoL) according to age (<70 versus ≥70 years) and sex. RESULTS: No significant differences in terms of PFS (P = 0.757), OS (P = 0.588) and overall response rates (ORRs) (P = 0.238) were observed between older and younger patients. No significant differences in PFS (P = 0.646), OS (P = 0.858) and ORRs (P = 0.649) were observed between females and males. The effect of treatment arm on survival outcomes was similar across age (P = 0.094) and sex groups (P = 0.469). Looking at specific adverse events, peripheral neuropathy occurred more frequently in younger patients (P = 0.020), anaemia in older patients (P = 0.044) and hand-foot syndrome in women (P = 0.021). Older patients were less likely to receive a post-discontinuation treatment (P = 0.010), especially in arm B (P = 0.026). The impact on QoL was better in arm A, irrespective of age and sex. CONCLUSION: The ARMANI trial supported the benefit of the investigated switch maintenance strategy irrespective of age and sex.
  • Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)
    Alberto Puccini, Giuseppe Viscardi, Oriana Ciani, Fabio Efficace, Angela Piattelli, Giordano Domenico Beretta, Davide Petruzzelli, Patrizia Popoli, Francesco De Lorenzo, Francesco Longo, Marco Zibellini, Lara Gitto, Antonella Brunello, Evaristo Maiello, Alberto Servetto, Martina Pagliuca, Alessandra Raimondi, Laura Marandino, Saverio Cinieri, Elisabetta Iannelli, Carla Ida Ripamonti, Paolo Bossi, Gianmauro Numico, Tiziana Latiano, Carmine Pinto, Silvana Quaglini, Laura Locati, Gualberto Gussoni, Gianluca Mignone, Pricivel M Carrera, Ethan Basch, Massimo Di Maio, Francesco Perrone
    BMJ Oncology, 2025
    ObjectivePatient-reported outcomes (PROs) are considered the gold standard for the assessment of subjective symptoms, quality of life (QoL) and patient well-being in both clinical trials and clinical practice. Here, we report key discussions and findings from the 21st National Conference of the Italian Association of Medical Oncology, held in Bologna on 21–22 June 2024, with a focus on the integration and impact of PROs in oncology research and clinical practice.Methods and analysisLeading national and international experts presented and analysed data regarding the use of PROs in clinical trials and routine oncology care. Topics included the role of electronic PROs (ePROs), digital therapeutics, financial toxicity as a PRO and methodologies for standardising QoL assessment. Insights were drawn from expert presentations, consensus discussions and practical experiences shared during the conference sessions.ResultsExperts emphasised that PROs should be included as key endpoints in clinical trials, with timely publication of results and standardised methodologies for analysis and interpretation. The conference highlighted the critical importance of incorporating PROs and QoL measures throughout the cancer care continuum—from screening to survivorship. In clinical practice, PROs improve patient-centred care and communication, particularly when oncologists are trained to interpret QoL data. The use of ePROs was noted as a valuable tool to support digital health interventions. Financial toxicity emerged as a significant PRO, with screening tools recommended to identify and support at-risk patients. Key organisational challenges were identified, including technological barriers, resource constraints and the need for responsive infrastructure to support real-time PRO integration.ConclusionThe implementation of PROs, including ePROs and financial toxicity assessments, is essential for advancing quality cancer care. Standardisation, digital innovation and targeted clinician education are critical to integrating PROs effectively in both research and clinical settings. Addressing infrastructural and technological challenges will be vital for optimising patient outcomes and ensuring optimal care across the cancer journey.
  • Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
    A. Raimondi, S. Lonardi, S. Murgioni, G.G. Cardellino, S. Tamberi, A. Strippoli, F. Palermo, G. De Manzoni, M. Bencivenga, A. Bittoni, C. Chiodoni, D. Lorenzini, K. Todoerti, P. Manca, S. Sangaletti, M. Prisciandaro, G. Randon, F. Nichetti, F. Bergamo, S. Brich, A. Belfiore, A. Bertolotti, D. Stetco, A. Guidi, T. Torelli, A. Vingiani, R.P. Joshi, M. Khoshdeli, N. Beaubier, M.C. Stumpe, F. Nappo, A.G. Leone, C.C. Pircher, G. Leoncini, G. Sabella, L. Airo’ Farulla, A. Alessi, F. Morano, A. Martinetti, M. Niger, M. Fassan, M. Di Maio, K. Kaneva, M. Milione, H. Nimeiri, C. Sposito, L. Agnelli, V. Mazzaferro, M. Di Bartolomeo, F. Pietrantonio
    Annals of Oncology, 2025
  • Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma
    Simone Oldani, Natalie Prinzi, Federica Morano, Sara Cingarlini, Anna Maria Di Giacomo, Monica Niger, Michele Prisciandaro, Alessandra Raimondi, Giovanni Randon, Chiara Carlotta Pircher, Michele Borghesani, Monica Valente, Elvira Rostanzo, Massimo Milione, Giovanna Sabella, Tommaso Cascella, Filippo Ghelardi, Carolina Sciortino, Eleonora Gusmaroli, Vincenzo Nasca, Filippo de Braud, Filippo Pietrantonio, Sara Pusceddu
    Future Oncology, 2025
    Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin with an aggressive behavior and high propensity for locoregional recurrence and metastasis. The therapeutic options in the metastatic disease are limited and are mainly based on immunotherapy or platinum-based doublets. Importantly, a significant proportion of patients experience resistance to single-agent immunotherapy highlighting the need for more active upfront combinations. The PANDORA trial [NCT 06086288] is an open label, multicenter, phase II trial evaluating the activity and safety of pembrolizumab combined with cisplatin or carboplatin and etoposide as first line treatment in patients with advanced MCC. The primary endpoint is objective response rate (ORR). Secondary objectives include overall survival (OS), progression free survival (PFS) and duration of response (DOR). Exploratory objectives include identification of immune and molecular biomarkers and assessment of Health-Related Quality of Life of pembrolizumab plus cisplatin/carboplatin and etoposide in participants with advanced/metastatic MCC. We planned to enroll 35 patients according to the study design. The combination of immune checkpoint inhibitors and chemotherapy was associated with better outcomes compared to either treatment alone in several cancer thanks to a potential synergy. Moving from a biological and clinical rationale, PANDORA may impact on the therapeutic landscape of MCC. Clinical Trial Registration: NCT06086288 (ClinicalTrials.gov).
  • Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
    Giovanni Randon, Sara Lonardi, Matteo Fassan, Federica Palermo, Stefano Tamberi, Elisa Giommoni, Carlotta Ceccon, Samantha Di Donato, Lorenzo Fornaro, Oronzo Brunetti, Ferdinando De Vita, Alessandro Bittoni, Claudio Chini, Andrea Spallanzani, Floriana Nappo, Valerie Bethaz, Antonia Strippoli, Tiziana Latiano, Giovanni Gerardo Cardellino, Francesco Giuliani, Federica Morano, Monica Niger, Alessandra Raimondi, Michele Prisciandaro, Chiara Carlotta Pircher, Carolina Sciortino, Silvia Marchesi, Silvio Ken Garattini, Giulia Airò, Rosalba Miceli, Maria Di Bartolomeo, Filippo Pietrantonio
    Lancet Oncology, 2024
  • A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection
    Marco Macagno, Valeria Pessei, Noemi Congiusta, Luca Lazzari, Sara Erika Bellomo, Fariha Idrees, Alessandro Cavaliere, Filippo Pietrantonio, Alessandra Raimondi, Eleonora Gusmaroli, Maria Giulia Zampino, Lorenzo Gervaso, Davide Ciardiello, Giuseppe Mondello, Armando Santoro, Nicola Personeni, Emanuela Bonoldi, Maria Costanza Aquilano, Emanuele Valtorta, Salvatore Siena, Andrea Sartore-Bianchi, Alessio Amatu, Erica Francesca Bonazzina, Katia Bruna Bencardino, Guido Serini, Silvia Marsoni, Ludovic Barault, Federica Di Nicolantonio, Federica Maione
    Diagnostics, 2024
  • Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
    Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Michele Prisciandaro, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, Francesca Bergamo, Alessandra Raimondi, Giuliana Ritorto, Beatrice Borelli, Veronica Conca, Clara Ugolini, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Luca Boni, Jerome Galon, Chiara Cremolini
    Journal of Clinical Oncology, 2024
  • Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials
    Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E. Langley, Yoon Young Choi, Kyoung-Mee Kim, Matthew Guy Nankivell, Giovanni Randon, Myeong-Cherl Kook, Ji Yeong An, Heike I. Grabsch, Michele Prisciandaro, Federico Nichetti, Sung Hoon Noh, Tae Sung Sohn, Sung Kim, Andrew Wotherspoon, Federica Morano, David Cunningham, Jeeyun Lee, Jae-Ho Cheong, Elizabeth Catherine Smyth, Filippo Pietrantonio
    European Journal of Cancer, 2024
  • Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort
    Francesco Panzuto, Elisa Andrini, Giuseppe Lamberti, Sara Pusceddu, Maria Rinzivillo, Fabio Gelsomino, Alessandra Raimondi, Alberto Bongiovanni, Maria Vittoria Davì, Mauro Cives, Maria Pia Brizzi, Irene Persano, Maria Chiara Zatelli, Ivana Puliafito, Salvatore Tafuto, Davide Campana
    Journal of Clinical Medicine, 2024
  • Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
    Giovanni Randon, Yoshiaki Nakamura, Rona Yaeger, Sara Lonardi, Chiara Cremolini, Elena Elez, Federico Nichetti, Filippo Ghelardi, Vincenzo Nasca, Francesca Bergamo, Veronica Conca, Javier Ros, Hideaki Bando, Giulia Maddalena, Simone Oldani, Michele Prisciandaro, Alessandra Raimondi, Alexa B. Schrock, Luca Agnelli, Henry Walch, Takayuki Yoshino, Filippo Pietrantonio
    Clinical Cancer Research, 2024
  • Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
    Filippo Ghelardi, Alessandra Raimondi, Federica Morano, Giovanni Randon, Alessandra Pannone, Marcello Guaglio, Giacomo Mazzoli, Vincenzo Nasca, Massimo Milione, Giuseppe Leoncini, Giovanna Sabella, Gabriella Francesca Greco, Bianca Rosa Lampis, Margherita Galassi, Sara Delfanti, Margherita Nannini, Rossana Intini, Dario Baratti, Maria Di Bartolomeo, Marcello Deraco, Filippo Pietrantonio
    Clinical Colorectal Cancer, 2023
  • Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
    Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro, Daniele Rossini, Vincenzo Formica, Mario Scartozzi, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Nicoletta Pella, Francesca Bergamo, Alessandra Raimondi, Ermenegildo Arnoldi, Lorenzo Antonuzzo, Cristina Granetto, Fable Zustovich, Monica Ronzoni, Silvana Leo, Federica Morano, Fotios Loupakis, Federica Buggin, Vittorina Zagonel, Matteo Fassan, Chiara Cremolini, Luca Boni, Filippo Pietrantonio, , Ermenegildo Arnoldi, Lorenzo Antonuzzo, Giuseppe Aprile, Antonio Ardizzoia, Carlo Aschele, Editta Baldini, Alberto Ballestrero, Alessandro Bertolini, Roberto Bordonaro, Giorgia Boscolo, Angela Buonadonna, Saverio Cinieri, Matteo Clavarezza, Domenico Corsi, Enrico Cortesi, Filippo De Braud, Samantha Di Donato, Alfredo Falcone, Adolfo Favaretto, Vincenzo Formica, Luca Frassineti, Antonio Frassoldati, Michela Frisinghelli, Teresa Gamucci, Luca Gianni, Filippo Giovanardi, Stefania Gori, Roberta Grande, Cristina Granetto, Silvana Leo, Francesco Leone, Sara Lonardi, Andrea Luciani, Carlo Milandri, Nicoletta Pella, Andrea Sartore-Bianchi, Mario Scartozzi, Nicola Silvestris, Emiliano Tamburini, Gianluca Tomasello, Giuseppe Tonini, Gianpaolo Tortora, Claudio Vergani, Albrto Zaniboni, Fable Zustovich
    Journal of Clinical Oncology, 2023
  • Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
    Alessandra Raimondi, Federico Nichetti, Arndt Stahler, Harpreet S. Wasan, Enrique Aranda, Giovanni Randon, Annika Kurreck, Angela M. Meade, Eduardo Díaz-Rubio, Monica Niger, Sebastian Stintzing, Federica Palermo, Tanja Trarbach, Michele Prisciandaro, Greta Sommerhäuser, David Fisher, Federica Morano, Filippo Pietrantonio, Dominik P. Modest
    European Journal of Cancer, 2023
  • Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials
    Alessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, Martina Carullo, Sara Lonardi, Federica Morano, Daniele Santini, Gianluca Tomasello, Monica Niger, Alberto Zaniboni, Francesca Daniel, Sara Bustreo, Letizia Procaccio, Matteo Clavarezza, Samanta Cupini, Michela Libertini, Federica Palermo, Filippo Pietrantonio, Chiara Cremolini
    European Journal of Cancer, 2023
  • Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
    Lorenzo Castagnoli, Simona Corso, Alma Franceschini, Alessandra Raimondi, Sara Erika Bellomo, Matteo Dugo, Federica Morano, Michele Prisciandaro, Silvia Brich, Antonino Belfiore, Andrea Vingiani, Maria Di Bartolomeo, Giancarlo Pruneri, Elda Tagliabue, Silvia Giordano, Filippo Pietrantonio, Serenella M. Pupa
    Cellular Oncology, 2023
  • HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
    Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, Simona Corso, Alessandra Raimondi, Enrico Berrino, Federica Morano, Cristina Migliore, Monica Niger, Lorenzo Castagnoli, Serenella Maria Pupa, Caterina Marchiò, Maria Di Bartolomeo, Eleonora Restuccia, Chiara Lambertini, Josep Tabernero, Silvia Giordano
    Clinical Cancer Research, 2023
  • TARGETED THERAPY IN CHOLANGIOCARCINOMA: CURRENT LANDSCAPE AND FUTURE HORIZON
    C.C. Pircher, C. Sposetti, F. Nichetti, F. Corti, A. Raimondi, M. Di Bartolomeo, E. Julien, M. Niger
    Annals of Research in Oncology, 2022
  • Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial
    Alessandra Raimondi, Giovanni Randon, Michele Prisciandaro, Filippo Pagani, Sara Lonardi, Carlotta Antoniotti, Silvia Bozzarelli, Andrea Sartore‐Bianchi, Marco Tampellini, Laura Fanchini, Roberto Murialdo, Matteo Clavarezza, Alberto Zaniboni, Rosa Berenato, Margherita Ratti, Fausto Petrelli, Lorenzo Antonuzzo, Monica Giordano, Alessandro Rossi, Maria Di Bartolomeo, Massimo Di Maio, Filippo Pietrantonio, Federica Morano
    International Journal of Cancer, 2022
  • Outpatient palliative care referral system (PCRS) for patients with advanced cancer: an impact evaluation protocol
    Cinzia Brunelli, Ernesto Zecca, Alessandra Pigni, Paola Bracchi, Mariangela Caputo, Silvia Lo Dico, Viviana Fusetti, Antonino Tallarita, Cristiana Bergamini, Marta Brambilla, Alessandra Raimondi, Monica Niger, Salvatore Provenzano, Pierangela Sepe, Sara Alfieri, Gabriele Tinè, Filippo De Braud, Augusto Tommaso Caraceni
    BMJ Open, 2022
  • Temozolomide Followed by Combination with Low-Dose Ipilimumab and Nivolumab in Patients with Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial
    Federica Morano, Alessandra Raimondi, Filippo Pagani, Sara Lonardi, Lisa Salvatore, Chiara Cremolini, Sabina Murgioni, Giovanni Randon, Federica Palermo, Lorenzo Antonuzzo, Nicoletta Pella, Patrizia Racca, Michele Prisciandaro, Monica Niger, Francesca Corti, Francesca Bergamo, Alberto Zaniboni, Margherita Ratti, Michele Palazzo, Celeste Cagnazzo, Maria Alessandra Calegari, Federica Marmorino, Iolanda Capone, Elena Conca, Adele Busico, Silvia Brich, Elena Tamborini, Federica Perrone, Massimo Di Maio, Massimo Milione, Maria Di Bartolomeo, Filippo de Braud, Filippo Pietrantonio
    Journal of Clinical Oncology, 2022
  • FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
    Carlotta Antoniotti, Marco M. Germani, Daniele Rossini, Sara Lonardi, Filippo Pietrantonio, Daniele Santini, Federica Marmorino, Giacomo Allegrini, Francesca Daniel, Alessandra Raimondi, Beatrice Borelli, Alberto Zaniboni, Veronica Conca, Jim Abraham, David Spetzler, Evaristo Maiello, Alessandra Boccaccino, Alessandro Passardi, Mirella Giordano, Emiliano Tamburini, Michael W. Korn, Gianluca Masi, Chiara Cremolini
    European Journal of Cancer, 2022
  • THE EMERGING ROLE OF IMMUNOTHERAPY IN GASTROESOPHAGEAL CANCER: STATE OF ART AND FUTURE PERSPECTIVE
    A. Raimondi, M. Prisciandaro, F. Pagani, G. Randon, F. Corti, F. Nichetti, M. Niger, F. Morano, F. Pietrantonio, M. Di Bartolomeo
    Annals of Research in Oncology, 2022
  • Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score
    A.G. Leone, F. Petrelli, A. Ghidini, A. Raimondi, E.C. Smyth, F. Pietrantonio
    ESMO Open, 2022
  • Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
    Michele Prisciandaro, Maria Antista, Alessandra Raimondi, Francesca Corti, Federica Morano, Giovanni Centonze, Giovanna Sabella, Alessandro Mangogna, Giovanni Randon, Filippo Pagani, Natalie Prinzi, Monica Niger, Salvatore Corallo, Erica Castiglioni di Caronno, Marco Massafra, Maria Di Bartolomeo, Filippo de Braud, Massimo Milione, Sara Pusceddu
    Frontiers in Oncology, 2022
  • Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study
    Paolo Manca, Salvatore Corallo, Sara Lonardi, Giovanni Fucà, Adele Busico, Alberto Giovanni Leone, Francesca Corti, Carlotta Antoniotti, Letizia Procaccio, Valeria Smiroldo, Margherita Ratti, Roberto Murialdo, Patrizia Racca, Filippo Pagani, Giovanni Randon, Antonia Martinetti, Elisa Sottotetti, Michele Prisciandaro, Margherita Ambrosini, Alessandra Raimondi, Federica Morano, Filippo Pietrantonio
    British Journal of Cancer, 2022
  • Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
    Giovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, Sara Lonardi, Chiara Cremolini, Margherita Ratti, Matteo Clavarezza, Roberto Murialdo, Andrea Sartore-Bianchi, Valeria Smiroldo, Rosa Berenato, Patrizia Racca, Francesca Bergamo, Salvatore Corallo, Maria Di Bartolomeo, Filippo de Braud, Federica Morano, Filippo Pietrantonio
    Oncologist, 2022
  • Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
    Claudio Vernieri, Giovanni Fucà, Francesca Ligorio, Veronica Huber, Andrea Vingiani, Fabio Iannelli, Alessandra Raimondi, Darawan Rinchai, Gianmaria Frigè, Antonino Belfiore, Luca Lalli, Claudia Chiodoni, Valeria Cancila, Federica Zanardi, Arta Ajazi, Salvatore Cortellino, Viviana Vallacchi, Paola Squarcina, Agata Cova, Samantha Pesce, Paola Frati, Raghvendra Mall, Paola Antonia Corsetto, Angela Maria Rizzo, Cristina Ferraris, Secondo Folli, Marina Chiara Garassino, Giuseppe Capri, Giulia Bianchi, Mario Paolo Colombo, Saverio Minucci, Marco Foiani, Valter Daniel Longo, Giovanni Apolone, Valter Torri, Giancarlo Pruneri, Davide Bedognetti, Licia Rivoltini, Filippo de Braud
    Cancer Discovery, 2022
  • Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma
    Raffaele Ratta, Elena Verzoni, Alessia Mennitto, Francesco Pantano, Antonia Martinetti, Alessandra Raimondi, Pierangela Sepe, Elisa Sottotetti, Roberta Mennitto, Daniele Morelli, Daniele Santini, Filippo G. de Braud, Giuseppe Procopio
    Tumori, 2021
  • Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
    D. Rossini, A. Boccaccino, A. Sbrana, F. Daniel, B. Borelli, A. Raimondi, D. Santini, V. Conca, G. Tomasello, S. Caponnetto, F. Marmorino, A. Zaniboni, A. Buonadonna, G. Masi, S. Lonardi, F. Pietrantonio, A. Falcone, A. Antonuzzo, C. Cremolini
    ESMO Open, 2021
  • Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
    Lorenza Di Guardo, Giovanni Randon, Francesca Corti, Viviana Vallacchi, Alessandra Raimondi, Giovanni Fucà, Marta Bini, Andrea Maurichi, Roberto Patuzzo, Gianfrancesco Gallino, Ilaria Mattavelli, Roberta Ruggeri, Martina Angi, Mara Cossa, Barbara Valeri, Carolina Cimminiello, Mario Santinami, Licia Rivoltini, Filippo Braud, Monica Rodolfo, Michele Del Vecchio
    Oncologist, 2021
  • Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
    A. Raimondi, G. Fucà, A.G. Leone, S. Lonardi, C. Antoniotti, V. Smiroldo, A. Amatu, M. Tampellini, G. Ritorto, R. Murialdo, M. Clavarezza, A. Zaniboni, R. Berenato, M. Ratti, S. Corallo, F. Morano, M. Di Bartolomeo, M. Di Maio, F. Pietrantonio
    ESMO Open, 2021
  • Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial
    Filippo Pietrantonio, Giovanni Fucà, Paolo Manca, Filippo Pagani, Alessandra Raimondi, Michele Prisciandaro, Giovanni Randon, Francesca Corti, Filippo de Braud, Chiara Cremolini, Rosalba Miceli
    Tumori, 2021
  • Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study
    Alessandra Raimondi, Salvatore Corallo, Sara Lonardi, Carlotta Antoniotti, Lorenza Rimassa, Alessio Amatu, Marco Tampellini, Patrizia Racca, Roberto Murialdo, Matteo Clavarezza, Alberto Zaniboni, Giuseppe Toscano, Gianluca Tomasello, Fausto Petrelli, Lorenzo Antonuzzo, Monica Giordano, Saverio Cinieri, Raffaella Longarini, Monica Niger, Maria Antista, Margherita Ambrosini, Filippo Pagani, Michele Prisciandaro, Giovanni Randon, Filippo de Braud, Maria Di Bartolomeo, Filippo Pietrantonio, Federica Morano
    Supportive Care in Cancer, 2021
  • Personalized therapeutic strategies in HER2-driven gastric cancer
    Stefano Ughetto, Cristina Migliore, Filippo Pietrantonio, Maria Apicella, Annalisa Petrelli, Laura D’Errico, Stefania Durando, Daniel Moya-Rull, Sara E. Bellomo, Sabrina Rizzolio, Tania Capelôa, Salvatore Ribisi, Maurizio Degiuli, Rossella Reddavid, Ida Rapa, Uberto Fumagalli, Stefano De Pascale, Dario Ribero, Carla Baronchelli, Giovanni Sgroi, Emanuele Rausa, Gian Luca Baiocchi, Sarah Molfino, Stefania Manenti, Maria Bencivenga, Michele Sacco, Claudia Castelli, Salvatore Siena, Andrea Sartore-Bianchi, Federica Tosi, Federica Morano, Alessandra Raimondi, Michele Prisciandaro, Annunziata Gloghini, Silvia Marsoni, Antonino Sottile, Ivana Sarotto, Anna Sapino, Caterina Marchiò, Paola Cassoni, Simonetta Guarrera, Simona Corso, Silvia Giordano
    Gastric Cancer, 2021
  • Tremelimumab and durvalumab combination for the non-operative management (Nom) of microsatellite instability (msi)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-arm, multi-cohort, phase ii infinity study
    Alessandra Raimondi, Federica Palermo, Michele Prisciandaro, Massimo Aglietta, Lorenzo Antonuzzo, Giuseppe Aprile, Rossana Berardi, Giovanni G. Cardellino, Giovanni De Manzoni, Ferdinando De Vita, Massimo Di Maio, Lorenzo Fornaro, Giovanni L. Frassineti, Cristina Granetto, Francesco Iachetta, Sara Lonardi, Roberto Murialdo, Elena Ongaro, Francesca Pucci, Margherita Ratti, Nicola Silvestris, Valeria Smiroldo, Andrea Spallanzani, Antonia Strippoli, Stefano Tamberi, Emiliano Tamburini, Alberto Zaniboni, Maria Di Bartolomeo, Chiara Cremolini, Carlo Sposito, Vincenzo Mazzaferro, Filippo Pietrantonio
    Cancers, 2021
  • Recent Advances in the Management of Typical and Atypical Lung Carcinoids
    Natalie Prinzi, Roberta Elisa Rossi, Claudia Proto, Giovanni Leuzzi, Alessandra Raimondi, Martina Torchio, Massimo Milione, Francesca Corti, Elena Colombo, Michele Prisciandaro, Tommaso Cascella, Carlo Spreafico, Teresa Beninato, Jorgelina Coppa, Giuseppe Lo Russo, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu
    Clinical Lung Cancer, 2021
  • The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer
    Paolo Manca, Salvatore Corallo, Adele Busico, Sara Lonardi, Francesca Corti, Carlotta Antoniotti, Letizia Procaccio, Matteo Clavarezza, Valeria Smiroldo, Gianluca Tomasello, Roberto Murialdo, Andrea Sartore-Bianchi, Patrizia Racca, Filippo Pagani, Giovanni Randon, Antonia Martinetti, Elisa Sottotetti, Federica Palermo, Federica Perrone, Elena Tamborini, Michele Prisciandaro, Alessandra Raimondi, Maria Di Bartolomeo, Federica Morano, Filippo Pietrantonio
    Clinical Cancer Research, 2021
  • Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
    Giovanni Fucà, Francesca Corti, Margherita Ambrosini, Rossana Intini, Massimiliano Salati, Elisabetta Fenocchio, Paolo Manca, Chiara Manai, Francesca Daniel, Alessandra Raimondi, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Andrea Spallanzani, Virginia Quarà, Carmen Belli, Marta Vaiani, Giuseppe Curigliano, Chiara Cremolini, Filippo De Braud, Maria Di Bartolomeo, Vittorina Zagonel, Sara Lonardi, Filippo Pietrantonio
    Journal for Immunotherapy of Cancer, 2021
  • FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis
    Filippo Pietrantonio, Giovanni Fucà, Daniele Rossini, Hans-Joachim Schmoll, Johanna C. Bendell, Federica Morano, Carlotta Antoniotti, Salvatore Corallo, Beatrice Borelli, Alessandra Raimondi, Federica Marmorino, Monica Niger, Alessandra Boccaccino, Gianluca Masi, Sara Lonardi, Luca Boni, Filippo Braud, Maria Di Bartolomeo, Alfredo Falcone, Chiara Cremolini
    Oncologist, 2021
  • Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S
    Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, Daniel V.T. Catenacci, Sarit Schwartz, Shankar Sellappan, Yuan Tian, Rosalba Miceli, Alessandro Pellegrinelli, Elisa Giommoni, Enrico Aitini, Francesca Spada, Gerardo Rosati, Alberto Marchet, Francesca Pucci, Alberto Zaniboni, Stefano Tamberi, Tiziana Pressiani, Gianni Sanna, Maurizio Cantore, Stefania Mosconi, Paola Bolzoni, Carmine Pinto, Lorenza Landi, Hector Josè Soto Parra, Luigi Cavanna, Salvatore Corallo, Antonia Martinetti, Todd A. Hembrough, Filippo Pietrantonio
    Tumori, 2021
  • Baseline characteristics and outcomes of cancer patients infected with sars-cov-2 in the lombardy region, italy (Aiom-l corona): A multicenter, observational, ambispective, cohort study
    Serena Di Cosimo, Barbara Tagliaferri, Daniele Generali, Fabiola Giudici, Francesco Agustoni, Antonio Bernardo, Karen Borgonovo, Gabriella Farina, Giovanna Luchena, Andrea Luciani, Franco Nolè, Laura Palmeri, Filippo Pietrantonio, Guido Poggi, Paolo Andrea Zucali, Emanuela Balletti, Giovanna Catania, Ottavia Bernocchi, Federica D’Antonio, Monica Giordano, Francesco Grossi, Angioletta Lasagna, Nicla La Verde, Mariangela Manzoni, Benedetta Montagna, Angelo Olgiati, Alessandra Raimondi, Irene Rampinelli, Elena Verri, Alberto Zaniboni, Massimo Di Maio, Giordano Beretta, Marco Danova
    Cancers, 2021
  • Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer
    Paolo Manca, Salvatore Corallo, Giovanni Randon, Sara Lonardi, Chiara Cremolini, Lorenza Rimassa, Francesca Bergamo, Carlotta Antoniotti, Valeria Smiroldo, Alberto Zaniboni, Roberto Murialdo, Marco Tampellini, Gianluca Tomasello, Matteo Clavarezza, Patrizia Racca, Maria Antista, Alessandra Raimondi, Michele Prisciandaro, Filippo Pagani, Federica Palermo, Francesca Gabriella Greco, Marta Vaiani, Maria Di Bartolomeo, Filippo de Braud, Giuseppina Calareso, Federica Morano, Filippo Pietrantonio
    European Journal of Cancer, 2021
  • Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori
    Alessandra Raimondi, Pierangela Sepe, Melanie Claps, Marco Maccauro, Gianluca Aliberti, Filippo Pagani, Giulia Apollonio, Giovanni Randon, Giorgia Peverelli, Ettore Seregni, Elena Verzoni, Giuseppe Procopio
    Tumori, 2020
  • Prospective translational study investigating molecular PrEdictors of resistance to first-line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)
    Pierangela Sepe, Antonia Martinetti, Alessia Mennitto, Elena Verzoni, Melanie Claps, Alessandra Raimondi, Elisa Sottotetti, Paolo Grassi, Valentina Guadalupi, Marco Stellato, Emma Zattarin, Massimo Di Maio, Giuseppe Procopio
    American Journal of Clinical Oncology Cancer Clinical Trials, 2020
  • Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials
    Salvatore Corallo, Giovanni Fucà, Federica Morano, Massimiliano Salati, Andrea Spallanzani, Annunziata Gloghini, Chiara Costanza Volpi, Desirè Viola Trupia, Riccardo Lobefaro, Vincenzo Guarini, Massimo Milione, Laura Cattaneo, Maria Antista, Michele Prisciandaro, Alessandra Raimondi, Carlo Sposito, Vincenzo Mazzaferro, Filippo de Braud, Filippo Pietrantonio, Maria Di Bartolomeo
    Oncologist, 2020
  • Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
    Filippo Pietrantonio, Fotios Loupakis, Giovanni Randon, Alessandra Raimondi, Massimiliano Salati, Dario Trapani, Filippo Pagani, Ilaria Depetris, Giulia Maddalena, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Francesca Corti, Vincenzo Guarini, Alessandro Bocconi, Antonio Marra, Carmen Belli, Andrea Spallanzani, Matteo Fassan, Sara Lonardi, Giuseppe Curigliano, Giovanni Fucà, Maria Di Bartolomeo, Filippo de Braud
    Oncologist, 2020
  • Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
    Filippo Pietrantonio, Federica Morano, Monica Niger, Salvatore Corallo, Maria Antista, Alessandra Raimondi, Michele Prisciandaro, Filippo Pagani, Natalie Prinzi, Federico Nichetti, Giovanni Randon, Martina Torchio, Francesca Corti, Margherita Ambrosini, Federica Palermo, Michele Palazzo, Lavinia Biamonte, Marco Platania, Carlo Sposito, Maurizio Cosimelli, Vincenzo Mazzaferro, Sara Pusceddu, Chiara Cremolini, Filippo de Braud, Maria Di Bartolomeo
    Clinical Colorectal Cancer, 2020
  • Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
    Alessandra Raimondi, Pierangela Sepe, Emma Zattarin, Alessia Mennitto, Marco Stellato, Melanie Claps, Valentina Guadalupi, Elena Verzoni, Filippo de Braud, Giuseppe Procopio
    Frontiers in Oncology, 2020
  • Differential diagnosis and management of diarrhea in patients with neuroendocrine tumors
    Sara Pusceddu, Roberta Elisa Rossi, Martina Torchio, Natalie Prinzi, Monica Niger, Jorgelina Coppa, Luca Giacomelli, Rodolfo Sacco, Antonio Facciorusso, Francesca Corti, Alessandra Raimondi, Michele Prisciandaro, Elena Colombo, Teresa Beninato, Marta Del Vecchio, Massimo Milione, Maria Di Bartolomeo, Filippo de Braud
    Journal of Clinical Medicine, 2020
  • Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study
    Alessandra Raimondi, Massimo Di Maio, Federica Morano, Salvatore Corallo, Sara Lonardi, Carlotta Antoniotti, Lorenza Rimassa, Andrea Sartore-Bianchi, Marco Tampellini, Giuliana Ritorto, Roberto Murialdo, Matteo Clavarezza, Alberto Zaniboni, Vincenzo Adamo, Gianluca Tomasello, Fausto Petrelli, Lorenzo Antonuzzo, Monica Giordano, Saverio Cinieri, Raffaella Longarini, Francesca Bergamo, Monica Niger, Maria Antista, Giorgia Peverelli, Filippo de Braud, Maria Di Bartolomeo, Filippo Pietrantonio
    European Journal of Cancer, 2020
  • Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: A case series analysis and literature review
    Alessandra Raimondi, Noemi Simeone, Marco Guzzo, Massimo Maniezzo, Paola Collini, Carlo Morosi, Francesca Gabriella Greco, AnnaMaria Frezza, Paolo G. Casali, Silvia Stacchiotti
    ESMO Open, 2020
  • Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial
    Maria Di Bartolomeo, Federica Morano, Alessandra Raimondi, Rosalba Miceli, Salvatore Corallo, Elena Tamborini, Federica Perrone, Maria Antista, Monica Niger, Alessandro Pellegrinelli, Giovanni Randon, Filippo Pagani, Antonia Martinetti, Giovanni Fucà, Filippo Pietrantonio, on behalf of ITACA-S study group
    Oncologist, 2020
  • Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
    Filippo Pietrantonio, Riccardo Lobefaro, Maria Antista, Sara Lonardi, Alessandra Raimondi, Federica Morano, Stefania Mosconi, Lorenza Rimassa, Sabina Murgioni, Andrea Sartore-Bianchi, Gianluca Tomasello, Raffaella Longarini, Gabriella Farina, Fausto Petrelli, Stefania Gori, Giovanni Randon, Salvatore Corallo, Filippo Pagani, Vincenzo Guarini, Federica Palermo, Antonia Martinetti, Marco Macagno, Ludovic Barault, Federica Perrone, Elena Tamborini, Massimo Milione, Federica Di Nicolantonio, Massimo Di Maio, Giovanni Fucà, Maria Di Bartolomeo, Filippo de Braud
    Clinical Cancer Research, 2020
  • Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
    Giovanni Randon, Giovanni Fucà, Daniele Rossini, Alessandra Raimondi, Filippo Pagani, Federica Perrone, Elena Tamborini, Adele Busico, Giorgia Peverelli, Federica Morano, Monica Niger, Maria Antista, Salvatore Corallo, Serena Saggio, Beatrice Borelli, Gemma Zucchelli, Massimo Milione, Giancarlo Pruneri, Maria Di Bartolomeo, Alfredo Falcone, Filippo de Braud, Chiara Cremolini, Filippo Pietrantonio
    Scientific Reports, 2019
  • Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?
    Alessandra Raimondi, Pierangela Sepe, Melanie Claps, Elena Verzoni, Giuseppe Procopio
    Expert Opinion on Biological Therapy, 2019
  • The landscape of actionable gene fusions in colorectal cancer
    Filippo Pagani, Giovanni Randon, Vincenzo Guarini, Alessandra Raimondi, Michele Prisciandaro, Riccardo Lobefaro, Maria Di Bartolomeo, Gabriella Sozzi, Filippo de Braud, Patrizia Gasparini, Filippo Pietrantonio
    International Journal of Molecular Sciences, 2019
  • Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
    Giuseppe Procopio, Giulia Apollonio, Francesco Cognetti, Rosalba Miceli, Michele Milella, Alessandra Mosca, Vincenzo Emanuele Chiuri, Alessandra Bearz, Franco Morelli, Cinzia Ortega, Francesco Atzori, Maddalena Donini, Raffaele Ratta, Alessandra Raimondi, Melanie Claps, Antonia Martinetti, Umberto Capitanio, Filippo G. de Braud, Vera Cappelletti, Elena Verzoni
    European Urology Oncology, 2019
  • The evaluation of response to immunotherapy in metastatic renal cell carcinoma: Open challenges in the clinical practice
    Alessandra Raimondi, Giovanni Randon, Pierangela Sepe, Melanie Claps, Elena Verzoni, Filippo de Braud, Giuseppe Procopio
    International Journal of Molecular Sciences, 2019
  • Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs
    Natalie Prinzi, Alessandra Raimondi, Marco Maccauro, Massimo Milione, Enrico Garanzini, Martina Torchio, Francesca Corti, Federico Nichetti, Giuseppe Lo Russo, Luca Giacomelli, Vincenzo Mazzaferro, Maria Di Bartolomeo, Ettore Seregni, Filippo de Braud, Sara Pusceddu
    Future Oncology, 2019
  • Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
    Filippo Pietrantonio, Federica Morano, Salvatore Corallo, Rosalba Miceli, Sara Lonardi, Alessandra Raimondi, Chiara Cremolini, Lorenza Rimassa, Francesca Bergamo, Andrea Sartore-Bianchi, Marco Tampellini, Patrizia Racca, Matteo Clavarezza, Rosa Berenato, Marta Caporale, Maria Antista, Monica Niger, Valeria Smiroldo, Roberto Murialdo, Alberto Zaniboni, Vincenzo Adamo, Gianluca Tomasello, Monica Giordano, Fausto Petrelli, Raffaella Longarini, Saverio Cinieri, Alfredo Falcone, Vittorina Zagonel, Maria Di Bartolomeo, Filippo de Braud
    JAMA Oncology, 2019
  • Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population
    Giorgia Peverelli, Alessandra Raimondi, Raffaele Ratta, Elena Verzoni, Marco Bregni, Enrico Cortesi, Giacomo Cartenì, Giuseppe Fornarini, Gaetano Facchini, Sebastiano Buti, Luca Galli, Marcello Tucci, Michele Prisciandaro, Giuseppe Procopio
    Clinical Genitourinary Cancer, 2019
  • The role of metastasectomy in advanced renal cell carcinoma
    Giulia Apollonio, Alessandra Raimondi, Elena Verzoni, Melanie Claps, Pierangela Sepe, Filippo Pagani, Raffaele Ratta, Francesco Montorsi, Filippo Guglielmo Maria De Braud, Giuseppe Procopio
    Expert Review of Anticancer Therapy, 2019
  • Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial
    Rosalba Miceli, Jiyeong An, Maria Di Bartolomeo, Federica Morano, Seung Tae Kim, Se Hoon Park, Min Gew Choi, Joon Ho Lee, Alessandra Raimondi, Giovanni Fucà, Tae Sung Sohn, Jae Moon Bae, Sung Kim, Do Hoon Lim, Won Ki Kang, Kyoung-Mee Kim, Filippo Pietrantonio, Jeeyun Lee
    Oncology Switzerland, 2019
  • Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei
    Alessandra Raimondi, Salvatore Corallo, Monica Niger, Maria Antista, Giovanni Randon, Federica Morano, Massimo Milione, Shigeki Kusamura, Dario Baratti, Marcello Guaglio, Chiara Cremolini, Federica Marmorino, Maria Di Bartolomeo, Marcello Deraco, Filippo De Braud, Filippo Pietrantonio
    Clinical Colorectal Cancer, 2019
  • Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program
    on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora, Davide Tassinari, Stefano Panni, Antonio Pazzola, Gianmarco Surico, Alessandra Raimondi, Ugo De Giorgi, Giuseppe Procopio
    Journal for Immunotherapy of Cancer, 2019
  • Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge
    Sara Pusceddu, Natalie Prinzi, Alessandra Raimondi, Francesca Corti, Roberto Buzzoni, Maria Di Bartolomeo, Ettore Seregni, Marco Maccauro, Jorgelina Coppa, Massimo Milione, Vincenzo Mazzaferro, Filippo de Braud
    Tumori, 2019
  • Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases
    Filippo Pietrantonio, Christian Cotsoglou, Giovanni Fucà, Salvatore Lo Vullo, Federico Nichetti, Massimo Milione, Jorgelina Coppa, Marta Vaiani, Alessandra Alessi, Michele Prisciandaro, Michele Droz-Dit Busset, Federica Morano, Salvatore Corallo, Silvia Lazzati, Maria Antista, Alessia Mennitto, Giovanni Randon, Alessandra Raimondi, Antonino Belfiore, Barbara Padovano, Federica Perrone, Luigi Mariani, Maria Di Bartolomeo, Filippo de Braud, Vincenzo Mazzaferro
    Clinical Colorectal Cancer, 2019
  • Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
    Francesca Corti, Federico Nichetti, Alessandra Raimondi, Monica Niger, Natalie Prinzi, Martina Torchio, Elena Tamborini, Federica Perrone, Giancarlo Pruneri, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu
    Cancer Treatment Reviews, 2019
  • Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase
    Sarit Schwartz, Chris Szeto, Yuan Tian, Fabiola Cecchi, Salvatore Corallo, Maria Alessandra Calegari, Maria Di Bartolomeo, Federica Morano, Alessandra Raimondi, Giovanni Fucà, Antonia Martinetti, Ivana De Pascalis, Maurizio Martini, Antonino Belfiore, Massimo Milione, Armando Orlandi, Ludovic Barault, Carlo Barone, Filippo de Braud, Federica Di Nicolantonio, Steve Benz, Todd Hembrough, Filippo Pietrantonio
    European Journal of Cancer, 2019
  • Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy
    Federica Morano, Salvatore Corallo, Sara Lonardi, Alessandra Raimondi, Chiara Cremolini, Lorenza Rimassa, Roberto Murialdo, Alberto Zaniboni, Andrea Sartore-Bianchi, Gianluca Tomasello, Patrizia Racca, Matteo Clavarezza, Vincenzo Adamo, Federica Perrone, Annunziata Gloghini, Elena Tamborini, Adele Busico, Antonia Martinetti, Federica Palermo, Fotios Loupakis, Massimo Milione, Giovanni Fucà, Maria Di Bartolomeo, Filippo de Braud, Filippo Pietrantonio
    Journal of Clinical Oncology, 2019
  • Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer
    Filippo Pietrantonio, Rosalba Miceli, Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E. Langley, Yoon Young Choi, Kyoung-Mee Kim, Matthew Guy Nankivell, Federica Morano, Andrew Wotherspoon, Nicola Valeri, Myeong-Cherl Kook, Ji Yeong An, Heike I. Grabsch, Giovanni Fucà, Sung Hoon Noh, Tae Sung Sohn, Sung Kim, Maria Di Bartolomeo, David Cunningham, Jeeyun Lee, Jae-Ho Cheong, Elizabeth Catherine Smyth
    Journal of Clinical Oncology, 2019
  • Atypical RAS mutations in metastatic colorectal cancer
    Filippo Pietrantonio, Rona Yaeger, Alexa B. Schrock, Giovanni Randon, Sandra Romero-Cordoba, Daniele Rossini, Giovanni Fucà, Jeffrey S. Ross, Daisuke Kotani, Russell Madison, Seung Tae Kim, Lisa Salvatore, Alessandra Raimondi, Filippo Pagani, Beatrice Borelli, Federica Perrone, Maria Di Bartolomeo, Vincent A. Miller, Siraj M. Ali, Jeeyun Lee, Takayuki Yoshino, Filippo de Braud, Alfredo Falcone, Jaclyn F. Hechtman, Chiara Cremolini
    JCO Precision Oncology, 2019
  • Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
    F. Morano, S. Corallo, M. Niger, L. Barault, M. Milione, R. Berenato, R. Moretto, G. Randon, M. Antista, A. Belfiore, A. Raimondi, F. Nichetti, A. Martinetti, L. Battaglia, F. Perrone, G. Pruneri, A. Falcone, M. Di Bartolomeo, F. de Braud, F. Di Nicolantonio, C. Cremolini, F. Pietrantonio
    Annals of Oncology, 2018
  • Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study
    Augusto Caraceni, Raffaella Speranza, Elio Spoldi, Cristina Sonia Ambroset, Stefano Canestrari, Mauro Marinari, Anna Maria Marzi, Luciano Orsi, Laura Piva, Mirta Rocchi, Danila Valenti, Gianluigi Zeppetella, Furio Zucco, Alessandra Raimondi, Leonor Vasconcelos Matos, Cinzia Brunelli, Augusto Caraceni, Martini Cinzia, Raffaella Speranza, Elio Spoldi, Donatella Giannunzio, Cristina Sonia Ambroset, Stefano Canestrari, Mauro Marinari, Cristina Sesana, Anna Maria Marzi, Mirta Rocchi, Luciano Orsi, Laura Piva, Danila Valenti, Gianluigi Zeppetella, Furio Zucco, Ines Pinna, Cinzia Brunelli, Alessandro Valle, Antonio Conversano, Stefano Guerini, Gianvito Romanelli, Carlo Tempestini, Gabriella Monolo, Michele Fortis, Gianbattista Cossolini, Loretta Gulmini, Maria Assunta Mariconti, Luca Moroni, Giancarla Moscatelli, Matteo Longo, Franco Rizzi, Leonardo Trentin, Marco Visentin, Massimo Bernardo, Daniela Degiovanni, Maurizio Mannocci Galeotti, Donato Valenti, Eugenia Malinverni, Carla Negretti, Anna Roman, Cristina Mantica, Gabriella Farina, Agostino Zambelli, Adriana Turriziani, Giuseppe Micheletto, Antonio Orlando, Barbara Rizzi, Fabio Conforti, Benigno Carrara, Nadia Bongiorni, Massimo Luzzani, Massimo Damini
    Journal of Pain and Symptom Management, 2018
  • The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review
    Federico Nichetti, Antonio Marra, Francesca Corti, Alessandro Guidi, Alessandra Raimondi, Natalie Prinzi, Filippo de Braud, Sara Pusceddu
    Targeted Oncology, 2018
  • A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors
    Sara Pusceddu, Francesco Barretta, Annalisa Trama, Laura Botta, Massimo Milione, Roberto Buzzoni, Filippo De Braud, Vincenzo Mazzaferro, Ugo Pastorino, Ettore Seregni, Luigi Mariani, Gemma Gatta, Maria Di Bartolomeo, Daniela Femia, Natalie Prinzi, Jorgelina Coppa, Francesco Panzuto, Lorenzo Antonuzzo, Emilio Bajetta, Maria Pia Brizzi, Davide Campana, Laura Catena, Harry Comber, Fiona Dwane, Nicola Fazio, Antongiulio Faggiano, Dario Giuffrida, Kris Henau, Toni Ibrahim, Riccardo Marconcini, Sara Massironi, Maja Primic Žakelj, Francesca Spada, Salvatore Tafuto, Elizabeth Van Eycken, Jan Maaten Van der Zwan, Tina Žagar, Luca Giacomelli, Rosalba Miceli, _ _, _ _, Francesca Aroldi, Alberto Bongiovanni, Rossana Berardi, Nicole Brighi, Sara Cingarlini, Carolina Cauchi, Federica Cavalcoli, Carlo Carnaghi, Francesca Corti, Marilina Duro, Maria Vittoria Davì, Chiara De Divitiis, Paola Ermacora, Anna La Salvia, Gabriele Luppi, Giuseppe Lo Russo, Federico Nichetti, Alessandra Raimondi, Vittorio Perfetti, Paola Razzore, Maria Rinzivillo, Sabine Siesling, Martina Torchio, Boukje Van Dijk, Otto Visser, Claudio Vernieri
    Endocrine Related Cancer, 2018
  • Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives
    Claudio Vernieri, Federico Nichetti, Alessandra Raimondi, Sara Pusceddu, Marco Platania, Franco Berrino, Filippo de Braud
    Critical Reviews in Oncology Hematology, 2018
  • Genomic markers of resistance to targeted treatments in gastric cancer: Potential new treatment strategies
    Alessandra Raimondi, Federico Nichetti, Giorgia Peverelli, Maria Di Bartolomeo, Filippo De Braud, Filippo Pietrantonio
    Pharmacogenomics, 2018
  • Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: A case report and literature review
    Alessandra Raimondi, Francesca Colombo, Giulia Pintarelli, Carlo Morosi, Salvatore L. Renne, Anna M. Frezza, Maristella Saponara, Angelo P. Dei Tos, Arabella Mazzocchi, Salvatore Provenzano, Paolo G. Casali, Silvia Stacchiotti
    Anti Cancer Drugs, 2018